<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875937</url>
  </required_header>
  <id_info>
    <org_study_id>2019/KEP/218</org_study_id>
    <secondary_id>2019-000898-23</secondary_id>
    <nct_id>NCT03875937</nct_id>
  </id_info>
  <brief_title>The Trauma INtramuscular Tranexamic Acid Clinical Trial</brief_title>
  <acronym>TraumaINTACT</acronym>
  <official_title>Pharmacokinetics of Intramuscular Tranexamic Acid in Trauma Patients: a Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St George's University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Versailles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JP Moulton Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intramuscular injection of tranexamic acid (TXA) would increase its use in situations where
      administration of intravenous drugs is difficult. The investigators aim to assess the
      population pharmacokinetics of intramuscular TXA in trauma patients.

      Primary endpoint: Serum TXA concentrations over time. Secondary endpoints: Local reactions at
      injection sites and adverse events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, open-label, multicentre, pharmacokinetic study conducted in the UK hospital.
      Potential eligible patients will have received a 1 gram IV dose of TXA at the scene of the
      injury or on arrival in hospital and a second dose is clinically indicated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 12, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, open-label, multicentre, pharmacokinetic study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of serum TXA concentrations over time.</measure>
    <time_frame>Blood samples will be taken pre-dose and up to 11 hours after IM TXA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Injection sites reactions</measure>
    <time_frame>death, discharge or day seven (whichever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events reported by type</measure>
    <time_frame>death, discharge or day 7 (whichever comes first)</time_frame>
    <description>adverse events will be coded using MedDRA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Traumatic Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid 1 gram intramuscularly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a 1 gram dose of TXA by IM injection at least 1 hour and 30 minutes after their initial IV injection received at the scene or on arrival to hospital. The IM dose will be given as two 5mL (0.5 gram each) injections into the thigh (rectus femoris or vastus lateralis), gluteal or deltoid muscles, depending on the clinical scenario (e.g. taking into account the type of injury). Injections should be given in a non-injured muscle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic 1 gram</intervention_name>
    <description>To be administered intramuscularly (2 injections)</description>
    <arm_group_label>Tranexamic acid 1 gram intramuscularly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (appear to be at least 16 years old) trauma patients who have received 1 gram of
             intravenous TXA for the management of haemorrhage in whom a second dose is clinically
             indicated are eligible.

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haleema Shakur-Still</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSHTM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Roberts</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSHTM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1FR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>intramuscular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Dataset used for main analysis will be made freely available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>freely available 1 year after main publication</ipd_time_frame>
    <ipd_access_criteria>Free login to website required for monitoring usage of data</ipd_access_criteria>
    <ipd_url>https://freebird.lshtm.ac.uk</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

